Physician profile
Christopher William Hawk
NPI 1306138441
$18,350.39
in general payments reported to CMS, 2019-2025
26 companies · $3,038 in 2025
The $3,038 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,187 · 2020: $1,340 · 2021: $2,013 · 2022: $1,352 · 2023: $3,966 · 2024: $3,454 · 2025: $3,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,018 · Consulting Fee: $1,290 · Education: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,018.15 |
| Consulting Fee | $1,290.00 |
| Education | $1,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $3,995.76 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Penumbra, INC. | $2,906.53 | 2019-2025 | Indigo System |
| Edwards Lifesciences Corporation | $2,738.75 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $2,496.36 | 2019-2025 | Navitor, Mitraclip, Portico |
| Medtronic, INC. | $1,138.53 | 2021-2025 | Corevalve Evolut R, Reveal Linq |
| Abiomed | $951.33 | 2022-2025 | Impella |
| Boston Scientific Corporation | $831.47 | 2019-2025 | General - Vascular Access, Watchman Access System, Varithena Administration Pack |
| Shockwave Medical, INC | $675.01 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Impulse Dynamics (USA) INC. | $510.05 | 2021-2023 | Optimizer |
| Medtronic Vascular, INC. | $402.95 | 2019-2020 | |
| Cardiovascular Systems INC. | $384.90 | 2019-2022 | |
| Stryker Corporation | $329.70 | 2025 | Flowtriever, Clottriever Bold Catheter, Flowtriever Catheter, S |
| Biosense Webster, INC. | $298.50 | 2019-2024 | Carto 3, Soundstar |
| Cardiva Medical, INC. | $250.28 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Savvywire, Cardiva Vascade 6/7f Vcs |
| Biotronik INC. | $166.31 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.06 | 2022-2025 | Lifevest |
| Ge Healthcare | $26.81 | 2022 | |
| Acutus Medical, INC. | $26.49 | 2022 | |
| Astellas Pharma US INC | $24.65 | 2021 | |
| Cardinal Health 200 LLC | $24.61 | 2021 | |
| Cordis US Corp. | $22.98 | 2023 | Mynxgrip |
| Davol INC. | $22.13 | 2025 | Arista |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Merit Medical Systems INC | $17.58 | 2020 | |
| Siemens Medical Solutions USA, INC. | $16.70 | 2022 | |
| Livanova USA, INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.